Claim against Dr. Reddy’s Laboratories dismissed over Revlimid in US
All claims against the company in the litigation have now been dismissed.
All claims against the company in the litigation have now been dismissed.
The new facility will be able to handle four times as many patients as the previous facility.
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Mock drills are being conducted across the country to review the preparedness for management of COVID-19
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Subscribe To Our Newsletter & Stay Updated